FDA Determines Regulatory Review Period for FROVA Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for FROVA, a human drug product, in response to patent extension applications submitted to the Director of Patents and Trademarks at the Department of Commerce.